英矽智能超额完成E轮融资，本轮累计募资总额约1.23亿美元

中国香港和上海，6月16日——由生成式人工智能驱动的临床阶段生物医药科技公司英矽智能（Insilico Medicine）今日宣布，已于近期完成E轮融资全部交割。在投资者的支持下，本轮募资总额约1.23亿美元，超额完成既定目标，进一步彰显了公司独特双引擎业务模式的价值，即结合生成式人工智能平台和深厚的自主创新药物发现能力，实现持续强化学习推动科学创新。

英矽智能本次E轮融资由亚洲最大的独立资产管理公司之一惠理集团（HKG: 0806）旗下的私募股权基金、浦东创投和浦发集团、锡创投和宜兴国控联合领投，还吸引了多元化的产业和科技领域投资者的积极参与，并持续得到英矽智能现有全球投资者的进一步支持。除上次公告披露的投资方外，本轮融资还获得了逹宏投资有限公司等新晋投资者，以及Prosperity7 Ventures等英矽智能现有投资者的加入。

本轮募得资金将用于推动英矽智能在人工智能平台升级和药物研发管线创新方面的突破。具体而言，部分资金将被用于完善英矽智能自主研发的人工智能模型和算法，同时升级和扩展其前沿自动化智能实验室，以进一步简化药物研发流程。与此同时，英矽智能将持续开展对自主研发和合作开发的药物管线的临床探索，加速在生物医药研发领域的突破性创新。

英矽智能创始人兼首席执行官Alex Zhavoronkov博士表示，“我们非常感谢新老投资者的持续支持与信任，他们与我们抱有同样的愿景，即致力推动AI驱动的药物研发和医疗保健。超额完成E轮融资，不仅将加速我们创新管线和AI技术的发展，也彰显了行业对我们独特能力的认可。我们将持续推动突破性疗法的发展，在医药领域产生深远影响。”

英矽智能联合首席执行官兼首席科学官任峰博士表示，“投资者们的正面反馈进一步增强了我们的信心。随着多条AI驱动的研发管线并行推进，我们有望成为首批成功将AI发现和设计的候选新药推进并完成临床验证的公司之一。”

此前，英矽智能已公布了多项关键里程碑，证明其自主研发的AI平台能显著降低成本、提升早期药物研发的效率。通过AI与自动化技术的深度融合，公司已建立了超过30条自主研发的管线，其中10个项目获得IND批准，包括一款已完成IIa期临床试验的候选药物用于治疗特发性肺纤维化，一款已完成全球多中心I期临床试验的候选药物用于治疗炎症性肠病，和多款正在推进临床研究的抗肿瘤候选药物。

英矽智能通过多元化商业模式，构建了可持续的收入来源，核心包括部分管线的对外授权，同时兼顾药物发现和管线开发合作、软件解决方案以及与非制药行业相关的其他合作。自2014年成立以来，英矽智能已发表200余篇经同行评审的论文，拥有及申请专利共计644项。

Cambridge, MA, June 16 — Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the close of its Series E financing round at a total of around $123 million, surpassing its initial target amid strong investor interest. The oversubscribed series E round further recognizes Insilico’s unique dual-engine business model, which combines a generative AI platform with deep in-house drug discovery capabilities to continuously enhance reinforcement learning, strengthen Pharma.AI, and drive scientific innovation.

The Series E financing was led by a private equity fund of Value Partners Group (HKG:0806), one of Asia’s largest independent asset management firms, with participation from a diverse group of new industry- and technology-focused investors, alongside continued support from Insilico’s existing global backers. Additional funding beyond the last announcement came from new investors including Grand Leader and others, as well as from Insilico’s existing investors, Prosperity7 Ventures and etc.

The Series E funding will be allocated to advance Insilico’s innovative drug pipeline and further develop its AI platform to drive innovation in the pharmaceutical industry. A portion of the resources will be dedicated to refining AI models and algorithms, as well as updating and expanding Insilico’s state-of-the-art automated laboratory to further streamline R&D processes. Simultaneously, Insilico will prioritize the clinical validation of its AI-driven proprietary and partnered drug programs, thereby driving impactful innovations in healthcare.

“We are extremely grateful for the continued support from our investors, both new and existing, who share our vision for the future of AI-driven drug discovery and healthcare,” said Alex Zhavoronkov, PhD, Founder and Co-CEO of Insilico Medicine. “The oversubscribed completion of the Series E round is a milestone that not only accelerates the growth of our innovative pipeline and AI technologies but also underscores the industry’s recognition of our capabilities. We are committed to advancing transformative therapies and driving meaningful impact across the pharmaceutical landscape.”

“Positive feedback from investors has further reinforced our confidence.” said Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine. “With multiple AI-driven R&D programs advancing in parallel, we are on track to become one of the first companies to successfully advance an AI-based drug candidate through clinical validation.”

Previously, Insilico announced key benchmarks demonstrating the ability of its proprietary AI platform to significantly reduce costs and improve efficiency in early drug discovery and development. By integrating AI and automation technologies, the company has built a wholly owned pipeline of over 30 assets, 10 of which have received IND clearance. This includes one asset that has completed a Phase IIa trial for idiopathic pulmonary fibrosis (IPF), another that has completed a multi-center Phase I trial for inflammatory bowel disease (IBD), and several additional oncology programs progressing into clinical trials.

Insilico has built sustainable revenue streams through a diversified business model centered on out-licensing deals for certain programs, taking into account drug discovery and pipeline development, software solutions, and other discovery related programs for non-pharma sectors. Since its inception in 2014, Insilico has published over 200 peer-reviewed papers and has held more than 640 patents and patent applications.